Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Staphylococcal protein A is a cell wall-associated protein derived from Staphylococcus aureus. It is a highly conserved bacterial virulence factor with multifunctional immunomodulatory properties. Protein A binds with high affinity to the Fc region of immunoglobulin G (IgG) and also interacts with the Fab region of certain B-cell receptors (VH3 family), thereby interfering with normal antibody function and immune responses[2][3][5]. This binding impairs opsonization and phagocytosis by sequestering antibodies away from their effector functions. Additionally, staphylococcal protein A can bind to other host proteins such as tumor necrosis factor alpha receptor 1 (TNFRSF1A) and von Willebrand factor[3][5]. Recombinant forms are produced in E. coli for research and therapeutic development purposes[2]. As an investigational drug (e.g., PRTX-100), it has been studied for its immunomodulatory effects in autoimmune diseases such as rheumatoid arthritis and idiopathic thrombocytopenic purpura[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on staphylococcal protein a.